Showing results (291-300 of 355) with videos related to

Sort By:
Pageof 36
Kidney International|January 17, 2014
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in childrenAditi Sinha, Jaya Bajpai, Savita Saini, et al.
ACR Open Rheumatology|October 19, 2020
Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT StudyPhilip Mease, M Elaine Husni, Soumya D Chakravarty, et al.
Infection and Immunity|January 24, 2008
Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungsSoumya D Chakravarty, Guofeng Zhu, Ming C Tsai, et al.
Clinical Rheumatology|February 29, 2020
A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitisA Deodhar, S D Chakravarty, C Cameron, et al.
Rheumatology Advances in Practice|May 20, 2024
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studiesXenofon Baraliakos, Dafna D Gladman, Soumya D Chakravarty, et al.
Arthritis Research & Therapy|August 16, 2023
Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b studyGeorg Schett, Warner Chen, Sheng Gao, et al.
The Journal of Rheumatology|August 15, 2022
Women With Psoriatic Arthritis Experience Higher Disease Burden Than Men: Findings From a Real-World Survey in the United States and EuropeLaure Gossec, Jessica A Walsh, Kaleb Michaud, et al.
Clinical Therapeutics|February 20, 2022
Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid ArthritisJong Bong Lee, Aaron Broadwell, Yijun Fan, et al.
Arthritis Research & Therapy|March 22, 2022
Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisM Elaine Husni, Atul Deodhar, Sergio Schwartzman, et al.
Paediatric Drugs|October 29, 2025
Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis DataHerta Crauwels, Sarah Ringold, Samantha Howard, et al.
Pageof 36